Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05008848 · ClinicalTrials.gov registry record · Phase 3
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
A Phase 3 study of Cigarette Smoking-Related Carcinoma, sponsored by Alliance for Clinical Trials in Oncology.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT05008848: Recruiting Phase 3 study of Cigarette Smoking-Related Carcinoma, sponsored by Alliance for Clinical Trials in Oncology.
NCT05008848 is a Phase 3 study of Cigarette Smoking-Related Carcinoma that is actively recruiting participants, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 600 participants, above the 439-participant average among 21 other Cigarette Smoking-Related Carcinoma trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05008848, a Phase 3 study of Cigarette Smoking-Related Carcinoma, is actively recruiting participants, sponsored by Alliance for Clinical Trials in Oncology.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke, quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.
Primary Outcome
Response will be defined as (1) urine cotinine levels \< 50 ng/ml or (2) urine cotinine levels \>=50 ng/ml and an urine anabasine level \< 2 ng/ml if a patient self-reports vaping use or the use of nicotine replacement therapy (NRT). Patients who do not return at 6 months post-quit date for the cotinine assessment (and anabasine, if applicable) will be deemed non-responders. The analysis population is defined as all randomized and eligible patients. The primary evaluation of the primary outcome
Conditions Studied
Interventions
- BEHAVIORAL Smoking Cessation Intervention
- OTHER Questionnaire Administration
- OTHER Health Promotion and Education
- OTHER Informational Intervention
Study Locations (20)
Idaho
- Saint Alphonsus Cancer Care Center-Boise - Boise
- Saint Alphonsus Cancer Care Center-Caldwell - Caldwell
- Kootenai Health - Coeur d'Alene - Coeur d'Alene
- Saint Alphonsus Cancer Care Center-Nampa - Nampa
- Kootenai Clinic Cancer Services - Post Falls - Post Falls
- Kootenai Clinic Cancer Services - Sandpoint - Sandpoint
Georgia
- Northeast Georgia Medical Center Braselton - Braselton
- Northeast Georgia Medical Center-Gainesville - Gainesville
- The Longstreet Clinic - Gainesville - Gainesville
- Low Country Cancer Care - Savannah
- Memorial Health University Medical Center - Savannah
Illinois
- Rush-Copley Medical Center - Aurora
- Carle BroMenn Outpatient Center - Bloomington
- Illinois CancerCare-Bloomington - Bloomington
- Illinois CancerCare-Canton - Canton
Colorado
- Banner North Colorado Medical Center - Greeley
- Banner North Colorado Medical Center - Loveland Campus - Loveland
Arizona
- Kingman Regional Medical Center - Kingman
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
California
- Saint Helena Hospital - St. Helena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2028-08-26 |
| Phase | Phase 3 |
What NCT05008848 shows while recruiting
NCT05008848 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 439-participant average among 21 other Cigarette Smoking-Related Carcinoma trials with a reported enrollment target (37% higher).
The record links to 1 condition, with Cigarette Smoking-Related Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Smoking Cessation Intervention is the first listed.
NCT05008848 names 20 study sites across 7 states, led by Idaho, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT05008848 about?
NCT05008848 is a clinical study titled "Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program". This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke, quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.
What is the current status of trial NCT05008848?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2022-04-01. Estimated completion is 2028-08-26.
What conditions does trial NCT05008848 study?
This clinical trial studies the following conditions: Cigarette Smoking-Related Carcinoma.
What interventions are being tested in trial NCT05008848?
The interventions under investigation include: Smoking Cessation Intervention (BEHAVIORAL), Questionnaire Administration (OTHER), Health Promotion and Education (OTHER), Informational Intervention (OTHER).
Who is sponsoring clinical trial NCT05008848?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05008848 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cigarette Smoking-Related Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05008848's enrollment target sits among peer trials
600 6th of 21 higher than 16 of 21 other Cigarette Smoking-Related Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cigarette Smoking-Related Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Innovative Conversational Agent (Quitbot) for Smoking Cessation
ACTIVE NOT RECRUITING · Phase 3
-
A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial
RECRUITING · NA
-
Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use E-cigarettes and Cannabis (Co-Tox Study)
RECRUITING
-
Sensory Tests of Cigarettes for Identification of Flavors in Current Daily Smoking Adults
RECRUITING · Early Phase 1
-
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
RECRUITING · Phase 4
-
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI